[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-gastricgastroesophageal-junction-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-gastricgastroesophageal-junction-adenocarcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100579861","phase-2-a-multicenter-randomized-controlled-phase-ii-trial-of-iparomlimab-and-tuvonralimab-ql1706-combined-with-sox-chemotherapy-versus-chemotherapy-alone-in-the-treatment-of-locally-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-100579861",false,"NCT06829797","A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(STAR-03)","STAR-03","Inclusion Criteria:\n\n* Voluntary participation in the study and signing of informed consent;\n* Age ≥18 years and ≤75 years;\n* Pathologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma;\n* Clinical staging of T3N+ or T4a any N, M0 (according to AJCC 8th edition staging), with potential radical resection confirmed by CT or MRI;\n* Have not received any anti-tumor therapy (e.g., surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy);\n* Planned to undergo surgery after completion of neoadjuvant therapy;\n* Be able to swallow pills normally;\n* ECOG-PS score 0-1;\n* Expected survival ≥ 12 months;\n* Normal major organ function.\n\nExclusion Criteria:\n\n* Known HER2 positivity;\n* Known peritoneal metastases or positive peritoneal cytology (CY1P0) or T4b (according to AJCC 8th edition);\n* Presence of unresectable factors including unresectable tumors, contraindications to surgery and refusal of surgery;\n* The presence of a pre-existing or concurrent malignancy, with the exception of cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and carcinoma in situ of the breast\n* History of gastrointestinal perforation, history of abdominal abscess or recent (within 3 months) occurrence of intestinal obstruction, or concomitant intestinal obstruction as indicated by imaging or clinical signs;\n* Patients with abnormal coagulation (International Normalized Ratio (INR) \\>2.0 or Prothrombin Time (PT) \\>16s), a bleeding tendency or currently receiving thrombolytic or anticoagulant therapy (prophylactic use of low-dose aspirin and low-molecular-weight heparin is allowed);\n* Clinically significant bleeding symptoms or significant bleeding tendency such as gastrointestinal bleeding, gastric ulcer bleeding, and vasculitis within 3 months prior to randomization into groups. Patients with positive fecal occult blood at baseline may be retested, and if the retest remains positive, gastroscopy will be required (except for patients who have had a gastroscopy within 3 months prior to enrollment to rule out this condition);\n* Arterial\u002Fvenous thrombotic events such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, and cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to randomization to group;\n* A known hereditary or acquired predisposition to bleeding and thrombosis (e.g., hemophilia, coagulation disorders, and thrombocytopenia);\n* The presence of active ulcers, unhealed wounds or fractures\n* Urinalysis showing urinary protein ≥++, confirmed by 24-hour urine protein quantification \\>1.0 g;\n* Active infections requiring antimicrobial therapy (e.g., antibacterial, antiviral, and antifungal medications);\n* Active hepatitis (Hepatitis B reference: HBsAg positive and HBV DNA ≥ 500 IU\u002FmL; Hepatitis C reference: HCV antibody positive and HCV viral copy number \\> upper limit of normal (ULN));\n* Congenital or acquired immunodeficiency (e.g., HIV-infected patients);\n* Planned or previous organ or allogeneic bone marrow transplant;\n* Current interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring hormonal therapy, or other conditions that may interfere with the assessment and management of immune-related pulmonary toxicity, such as pulmonary fibrosis, opportunistic pneumonia (e.g., occlusive bronchiectasis), pneumoconiosis, drug-associated pneumonia, and idiopathic pneumonitis, or active pneumonitis or severe pulmonary impairment as demonstrated by CT at screening; Active tuberculosis;\n* Any active autoimmune disease or history of autoimmune disease with potential for relapse;\n* Treatment with immunosuppressive drugs or systemic corticosteroids (\\>10 mg\u002Fday of prednisone or equivalent) within 7 days prior to randomization to group;\n* Use of a strong CYP3A4 inducer within 2 weeks prior to randomization subgroup or use of a strong CYP3A4 inhibitor within 1 week prior to randomization subgroup\n* Oral or intravenous administration of therapeutic antibiotics within 4 weeks prior to randomization to subgroups, except for prophylactic antibiotics administered intravenously for no more than 48 hours\n* Known allergy to any study drug or excipient;\n* Participation in a clinical study of another drug within 4 weeks prior to randomization to group;\n* Being a lactating female.","ALL","18 Years","75 Years",{"count":21,"type":22},96,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","To explore the efficacy of Iparomlimab and Tuvonralimab (QL1706) in combination with SOX chemotherapy versus chemotherapy alone for the neoadjuvant treatment of locally-progressed gastric\u002Fgastroesophageal union adenocarcinomas by evaluating the complete pathologic remission rate (pCR).",[28],"Locally Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma","RECRUITING","2026-04-24",{"date":32,"type":33},"2026-04-29","ACTUAL",{"date":35,"type":33},"2025-03-11",{"date":37,"type":22},"2028-02-29",{"name":39,"class":40},"Shandong Provincial Hospital","OTHER_GOV",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":41},"100574999","phase-2-clinical-study-of-low-dose-interval-radiotherapy-combined-with-tirelizumab-and-sox-chemotherapy-neoadjuvant-therapy-for-locally-advanced-gastricgastroesophageal-junction-adenocarcinoma-100574999","NCT06766578","Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma","Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma(STAR-02)","STAR-02","Inclusion Criteria:\n\n* Patients voluntarily participated in the study and signed informed consent with good compliance and follow-up;\n* Adenocarcinoma of the gastric\u002Fgastroesophageal junction confirmed by endoscopic pathology (tumor located in the lesser bend of the stomach other than pylorus or the gastroesophageal junction) (Note: Pathology in other hospitals must be consulted by our hospital);\n* Patients with cT4N+M0 AJCC stage 8 combined with endoscopic, CT, MRI, or PETCT findings;\n* Age ≥18 years, ≤75 years, male and female;\n* ECOG PS score 0-1;\n* Presence of measurable and\u002For unmeasurable lesions as defined by the efficacy evaluation criteria for solid tumors (Recist 1.1);\n* Has not received any prior systemic antitumor therapy (including but not limited to systemic chemotherapy, radiotherapy, molecular targeted drug therapy, immunotherapy, biotherapy, topical therapy, or other investigational therapeutic drugs;\n* The functions of vital organs meet the following requirements (no blood components and cell growth factors are allowed to be used 2 weeks before screening) : Neutrophil absolute count (ANC) ≥ 1.5×10 9\u002FL; Platelets ≥100×10 9\u002FL; Hemoglobin ≥9g\u002FdL; Serum albumin ≥2.8g\u002FdL; Total bilirubin ≤ 1.5 ×ULN, ALT, AST and\u002For AKP≤2.5 ×ULN; serum creatinine ≤1.5 ×ULN or creatinine clearance ≥60mL\u002Fmin (calculated according to the Cockcroft-Gault formula); International standardized ratio (INR) and activated partial thrombin time (APTT) ≤1.5×ULN (INR can be screened in the expected treatment range of anticoagulants for stable doses of anticoagulants such as low molecular weight heparin or warfarin);\n* Fertile female subjects shall perform a urine or serum pregnancy test within 72 hours prior to receiving the first study drug, prove negative, and be willing to use an effective method of contraception during the trial period up to 5 months after the last drug administration.Male subjects whose partner is a woman of reproductive age should use an effective method of contraception during the trial period and for 7 months after the last dose.\n\nExclusion criteria\n\n* a history of surgery for gastric\u002Fesophagogastric junction tumors;\n* Previous history of fistula caused by primary tumor invasion;\n* Higher risk of gastrointestinal bleeding and perforation;\n* Poor nutritional status, BMI less than 18.5kg\u002Fm2, or PG-SGA score ≥9;\n* Major surgery or severe trauma within 4 weeks prior to first use of the study drug;\n* Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage;\n* has received or is currently receiving any of the following previous treatments: anti-PD-1 or anti-PD-L1 antibody therapy, chemotherapy, radiotherapy, targeted therapy;\n* Received any investigational drug within 4 weeks prior to first use of the investigational drug;\n* subjects requiring systemic treatment with corticosteroids (\\> 10mg prednisone equivalent daily dose) or other immunosuppressants within 2 weeks prior to initial use of the study drug, except for corticosteroids for esophageal\u002Fgastric local inflammation and for the prevention of allergy and nausea and vomiting.Other special circumstances, need to communicate with the bid. In the absence of active autoimmune disease, inhaled or topical steroids and adrenocorticosteroid replacement at doses \\> 10mg\u002F d of prednisone efficacy are permitted;\n* those who have received antitumor vaccine or have received live vaccine within 4 weeks prior to the first administration of the study drug;\n* have any active autoimmune disease or a history of autoimmune disease (such as interstitial pulmonary inflammation, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); Except patients with vitiligo or recovered asthma\u002Fallergy of the same age without any intervention as adults;Patients with autoimmune mediated hypothyroidism treated with stable doses of thyroid hormone replacement and type 1 diabetes treated with stable doses of insulin could be included;\n* have a history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation or allogeneic bone marrow transplantation;\n* any condition requiring systemic treatment with corticosteroids (more than 10 mg\u002F day of prednisone or its equivalent) or other immunosuppressant treatment within 14 days prior to treatment (except local, ocular, intraarticular, intranasal and inhaled corticosteroids with minimal systemic uptake); Prophylactic short-term (≤7 days) use of corticosteroids (e.g., to prevent contrast allergy) or for the treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to allergen exposure);\n* subjects with uncontrolled cardiac clinical symptoms or disease, such as (1) NYHA II or above heart failure (2) unstable angina pecina (3) myocardial infarction within 1 year (4) clinically significant ventricular arrhythmias or ventricular arrhythmias requiring clinical intervention;\n* Severe infection (CTCAE \\> level 2), such as severe pneumonia, bacteremia, and infectious complications requiring hospitalization, occurred within 4 weeks prior to initial use of the study drug; Chest imaging at baseline suggested active lung inflammation and signs and symptoms of infection requiring oral or intravenous antibiotic treatment within 2 weeks prior to enrollment, except for prophylactic antibiotic use;\n* a history of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis or other uncontrolled acute lung disease;\n* Patients with active pulmonary tuberculosis infection found by history or CT examination, or patients with active pulmonary tuberculosis infection history within 1 year before enrollment, or patients with active pulmonary tuberculosis infection history more than 1 year ago but without formal treatment;\n* Subjects with active hepatitis B (HBV DNA≥2000 IU\u002FmL or 10 4 Copies \u002FmL), hepatitis C (positive hepatitis C antibody, and HCV-RNA higher than the lower limit of detection method);\n* Abnormal values of sodium, potassium and calcium greater than grade 1 in laboratory tests within 2 weeks before enrollment, which could not be improved after treatment;\n* known allergy to macromolecular protein preparations, or to any COMPONENT of PD-1, or allergy, hypersensitivity or contraindication to oxaliplatin or capecitabine or any component used in their preparations;\n* A prior diagnosis of any other malignancy, other than malignancies with a low risk of metastasis and death (5-year survival \\> 90%), such as adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix;\n* pregnant or lactating women; Fertile subjects unwilling or unable to use effective contraception;\n* According to the investigator's judgment, subjects have other factors that may cause them to be forced to terminate the study, such as other serious diseases (including mental diseases) requiring combined treatment, other recent serious diseases (such as myocardial infarction and cerebrovascular accident) with high risk of recurrence, seriously abnormal laboratory test values, family or social factors, which may affect subjects' safety or the collection of test data.",{"count":51,"type":22},32,[25],"To evaluate the initial efficacy and safety of neoadjuvant low-dose interval radiotherapy combined with tirelizumab and SOX chemotherapy in locally advanced gastric\u002Fgastroesophageal junction adenocarcinoma.",[28],{"date":32,"type":33},{"date":57,"type":33},"2024-12-30",{"date":59,"type":22},"2027-12-31",{"name":39,"class":40},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":70,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100611696","phase-2-phase-ii-basket-trial-zanidatamab-plus-tislelizumab-in-her2-positive-gi-tumors-union-her2-basket-100611696","NCT07243938","Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","A Prospective, Multi-cohort Clinical Study to Explore the Preliminary Efficacy and Safety of Zanidatamab in Combination With Tislelizumab for HER2-Positive GI Tumors: the UNION-HER2-BASKET Study","Inclusion Criteria:\n\n* Clinical diagnosis of gastric cancer and colorectal cancer\n* Aged 18 to 75 years:\n* Able to sign a written informed consent form and understand and comply with the requirements and evaluation schedule of this study\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n* HER2-Positive: Immunohistochemistry (IHC) 3+ or IHC 2+ with FISH+ or NGS testing for high expression\n* Locally advanced rectal cancer cohort:\n\n  1. Histopathologically confirmed rectal adenocarcinoma\n  2. Tumor tissue confirmed by immunohistochemistry (IHC) as pMMR (high expression of MLH1, MSH2, MSH6, and PMS2 proteins), or confirmed by PCR or NGS as MSI-L or MSS\n  3. Tumor lower margin ≤10 cm from anal margin confirmed by colonoscopy, digital rectal examination, or MRI\n  4. Clinical stage cT3-4N0M0\u002FcTanyN+M0 (TNM staging per UICC\u002FAJCC 8th edition; T and N stages assessed by MRI)\n  5. Patients with one or more risk factors identified by MRI assessment: T4, tumor involvement of the mesorectal fascia (high MRF expression), extramural vascular invasion (high EMVI expression), ≥4 regional lymph node metastases (cN2), high lateral lymph node expression, or tumor margin ≤5 cm from the anal verge with strong organ preservation intent\n  6. No prior antitumor therapy for rectal cancer (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.; excludes traditional Chinese medicine\u002Fformulated Chinese medicine treatment)\n* Locally Advanced Gastric\u002FGastroesophageal Junction Cancer Cohort:\n\n  1. Histopathologically confirmed adenocarcinoma of the stomach or gastroesophageal junction\n  2. Clinical stage III-IVa (i.e., TNM staging T3\\~4aN+M0 or T4bNanyM0, refer to UICC\u002FAJCC 8th edition)\n  3. No prior antitumor therapy for gastric or gastroesophageal junction adenocarcinoma (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.; excludes traditional Chinese medicine\u002FChinese patent medicine treatment)\n* Advanced colorectal cancer cohort:\n\n  1. Histopathologically confirmed advanced colorectal cancer\n  2. Previous systemic anticancer therapy for metastatic colorectal cancer with documented failure, including fluoropyrimidine, oxaliplatin, irinotecan, cetuximab, or bevacizumab (excluding contraindications). Prior anti-HER2 therapy permitted\n  3. At least one measurable lesion defined according to RECIST 1.1\n  4. Expected survival \\> 3 months\n* Good organ function within ≤7 days prior to first study drug administration, as demonstrated by the following laboratory values:\n\n  1. No blood or platelet transfusions or growth factor support therapy within ≤14 days prior to blood sample collection during the screening period, and must meet:\n  2. ANC ≥ 1.5 x 10⁹\u002FL\n  3. Platelet count ≥ 100 x 10⁹\u002FL\n  4. Hemoglobin ≥ 90 g\u002FL\n  5. Serum creatinine ≤ 1.5 times the upper limit of normal (ULN)\n  6. AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases)\n  7. Serum total bilirubin ≤ 1.5 times ULN (≤ 3 times ULN for patients with liver metastases)\n  8. International Normalized Ratio (INR) ≤ 1.5 or Prothrombin Time ≤ 1.5 times ULN\n  9. Activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN\n  10. Serum albumin ≥ 30 g\u002FL\n* Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose and must be willing to use highly effective contraception during the trial and for 120 days after the last dose. Male subjects with partners of childbearing potential must be surgically sterilized or agree to use highly effective contraception during the trial and for 120 days after the last dose.\n\nExclusion Criteria:\n\nSubjects with any of the following conditions are ineligible for inclusion in this study:\n\n* History of or concurrent other malignancies, except for basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or carcinoma in situ, provided complete remission was achieved at least 5 years prior to screening and no additional treatment is required or anticipated during the study period.\n* Any of the following cardiovascular criteria:\n\n  1. Cardiac chest pain occurring ≤28 days prior to the first study drug administration, defined as moderate pain limiting daily activities or exercise\n  2. Symptomatic pulmonary embolism within ≤28 days prior to the first dose of study drug\n  3. History of any acute myocardial infarction within ≤6 months prior to the first dose of study drug\n  4. History of any New York Heart Association (NYHA) Class III or IV heart failure within ≤6 months prior to the first dose of study drug\n  5. Any ventricular arrhythmia event of severity ≥ Grade 2 within ≤ 6 months prior to the first dose of the study drug\n  6. History of any cerebrovascular accident within ≤6 months prior to the first dose of the study drug\n  7. Corrected QT interval (QTc) (corrected using Fridericia's formula) ≥ 470 msec in females or ≥ 450 msec in males\n\n  i) Note: If any patient's initial ECG shows a QTc interval \\> 450 msec (male) or \\> 470 msec (female), a follow-up ECG will be performed to verify the result h) Left ventricular ejection fraction (LVEF) ≤50% as assessed by multi-gated acquisition (MUGA) scan or echocardiogram (ECHO). Follow-up assessment must use the same modality as the baseline assessment\n* Any syncope or seizure occurring ≤28 days prior to the first study drug administration.\n* Active autoimmune disease requiring systemic treatment within the past 2 years.\n* Known history of human immunodeficiency virus (HIV) infection\n* Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers (HBV DNA \\> 500 IU\u002FmL) or active HCV carriers with detectable HCV RNA; Note: Inactive hepatitis B surface antigen (HBsAg) carriers and treated, stable hepatitis B patients (HBV DNA \\\u003C 500 IU\u002FmL) are eligible for enrollment\n* History of interstitial lung disease, non-infectious pneumonia, or uncontrolled pulmonary conditions, including pulmonary fibrosis, acute pulmonary disease, etc.\n* Severe chronic or active infections (including tuberculosis) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days prior to the first study drug dose. Note: Antiviral therapy is permitted for patients with viral hepatitis.\n* Any condition requiring systemic treatment with corticosteroids (prednisone or equivalent \\>10 mg\u002Fday) or other immunosuppressive agents within ≤14 days prior to the first dose of study drug\n* Hypersensitivity to any component of tislelizumab, zanidatamab，capecitabine, S-1, oxaliplatin, or any component of the container\n* Any major surgery requiring general anesthesia within ≤28 days prior to the first dose of study drug\n* Bleeding, thrombotic disorders, or use of anticoagulants (e.g., warfarin) or similar agents requiring therapeutic INR monitoring within 6 months prior to the first dose of study drug\n* History of allogeneic stem cell transplantation or organ transplantation\n* Live vaccine administration within ≤28 days prior to the first study drug dose. Note: Seasonal influenza vaccines, broadly classified as inactivated vaccines, are permitted. Inactivated COVID-19 vaccines are permitted. mRNA COVID-19 vaccines are not permitted. Intranasal influenza vaccines are live vaccines and are not permitted.\n* Concurrent participation in another clinical study, unless it is an observational (non-interventional) study or the participant is in the follow-up period of an interventional study\n* Inability to swallow tablets or diseases significantly affecting gastrointestinal function\n* Pregnant or lactating women\n* Other conditions deemed ineligible by the investigator.\n* Locally Advanced Rectal Cancer Cohort:\n\n  1. Previous treatment for rectal cancer, or clinical or imaging evidence of existing or potential distant metastasis\n  2. Clinical or imaging evidence of intestinal obstruction, gastrointestinal perforation with bleeding, prior abdominal abscess, or recent (within 3 months) occurrence of gastrointestinal perforation, abdominal abscess, or intestinal obstruction; or investigator assessment indicating high risk of perforation or bleeding\n  3. Assessed by the investigator as initially unresectable or unable to tolerate surgery\n  4. Patient assessed by the investigator as having factors rendering them unsuitable for radiotherapy\n  5. The patient has ≥2 concurrent colorectal cancer lesions\n  6. Patient has contraindications for MRI examination\n* Locally Advanced Gastric\u002FGastroesophageal Junction Cancer Cohort:\n\n  1. Previous treatment for gastric\u002Fgastroesophageal junction cancer, or clinical\u002Fimaging evidence of existing or potential distant metastasis\n  2. Clinical or imaging evidence of intestinal obstruction, gastrointestinal perforation, or bleeding; prior abdominal abscess; or recent (within 3 months) gastrointestinal perforation, abdominal abscess, or intestinal obstruction; or investigator assessment indicating high risk of perforation or bleeding\n  3. Initial inoperability as assessed by the investigator, or inability of the patient to tolerate surgery\n* Advanced colorectal cancer cohort:\n\n  1. Patients with any prior histopathological or hematological ctDNA testing demonstrating mismatch repair gene deficiency (dMMR) or microsatellite instability (MSI-H)\n  2. Presence of active leptomeningeal disease or uncontrolled brain metastases. Patients with previously treated brain metastases may be eligible if imaging shows stability, confirmed by repeat imaging demonstrating no progression for at least 4 weeks (Note: repeat imaging must occur during the study screening period).",{"count":69,"type":22},70,[25],"This study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy\u002Fradiotherapy for patients with HER2-positive locally advanced or metastatic gastrointestinal tumors.",[73,28,74,75],"Locally Advanced Rectal Cancer (LARC)","Metastatic Colorectal Cancer (mCRC)","Neoadjuvant Therapy","NOT_YET_RECRUITING","2025-11-21",{"date":79,"type":33},"2025-11-24",{"date":81,"type":22},"2026-01-15",{"date":83,"type":22},"2031-06-01",{"name":85,"class":86},"Tao Zhang","OTHER"]